Lymph nodes and gastric cancer

Journal of Surgical Oncology

Volumn 99, Issue 4, 2009, Pages 199-206

  Coburn, Natalie G ^a,b,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Gastric neoplasm; Lymph nodes; Surgery

Indexed keywords

FLUOROURACIL;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; ESOPHAGOGASTRODUODENOSCOPY; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENTINEL LYMPH NODE; STOMACH CANCER;

CHEMOTHERAPY, ADJUVANT; DECISION MAKING; DIAGNOSTIC IMAGING; HUMANS; LAPAROSCOPY; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SENTINEL LYMPH NODE BIOPSY; STOMACH NEOPLASMS;

EID: 62749177310     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21224     Document Type: Review

References (99)

1. Forman D, Burley VJ: Gastric cancer: Global pattern of the disease and an overview of environmental risk factors. Baillieres Best Pract Res Clin Gastroenterol 2006;20:633-649.
2. Powell FC, Cooper AJ, Massa MC, et al.: Sister Mary Joseph's nodule: A clinical and histologic study. J Am Acad Dermatol 1984;10:610-615.
3. Baumgart DC, Fischer A: Virchow's node. Lancet 2007;370:1568.
4. Hartgrink HH, van de Velde CJ: Status of extended lymph node dissection: Locoregional control is the only way to survive gastric cancer. J Surg Oncol 2005;90:153-1565.
5. Mikulicz J: Beitrage zur technik der operation des magencarcinoms. Arch Klin Chir Berl 1898:524-532.
6. Onate-Ocana LF, Aiello-Crocifoglio V, Mondragon-Sanchez R, et al.: Survival benefit of D2 lympadenectomy in patients with gastric adenocarcinoma. Ann Surg Oncol 2000;7:210-217.
7. de Gara CJ, Hanson J, Hamilton S: A population-based study of tumor-node relationship, resection margins, and surgeon volume on gastric cancer survival. Am J Surg 2003;186:23-27.
8. Seto Y, Nagawa H, Muto T: Impact of lymph node metastasis on survival with early gastric cancer. World J Surg 1997;21:186-189, discussion 190.
9. Siewert JR, Bottcher K, Stein HJ, et al.: Relevant prognostic factors in gastric cancer: Ten-year results of the German gastric cancer study. Ann Surg 1998;228:449-461.
10. Kim DY, Joo JK, Seo KW, et al.: T4 gastric carcinoma: The benefit of non-curative resection. ANZ J Surg 2006;76:453-457.
11. Jensen EH, Tuttle TM: Preoperative staging and postoperative surveillance for gastric cancer. Surg Oncol Clin N Am 2007;16:329-342.
12. NCCN clinical practice guidelines in oncology. vol.2.2007. Available from: http://www.nccn.org/professionals/physician-gls/PDF/gastric.pdf.
13. Bhandari S, Shim CS, Kim JH, et al.: Usefulness of threedimensional, multidetector row CT (virtual gastroscopy and multiplanar reconstruction) in the evaluation of gastric cancer: A comparison with conventional endoscopy, EUS, and histopathology. Gastrointest Endosc 2004;59:619-626.
14. Chen J, Cheong JH, Yun MJ, et al.: Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography. Cancer 2005;103:2383-2390.
15. Kim SK, Kang KW, Lee JS, et al.: Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging 2006;33:148-155.
16. Lee JH, Paik YH, Lee JS, et al.: Candidates for curative resection in advanced gastric cancer patients who had equivocal para-aortic lymph node metastasis on computed tomographic scan. Ann Surg Oncol 2006;13:1163-1167.
17. Kim AY, Han JK, Seong CK, et al.: MRI in staging advanced gastric cancer: Is it useful compared with spiral CT? J Comput Assist Tomogr 2000;24:389-394.
18. Motohara T, Semelka RC: MRI in staging of gastric cancer. Abdom Imaging 2002;27:376-383.
19. Tatsumi Y, Tanigawa N, Nishimura H, et al.: Preoperative diagnosis of lymph node metastases in gastric cancer by magnetic resonance imaging with ferumoxtran-10. Gastric Cancer 2006;9:120-128.
20. Shoda H, Kakugawa Y, Saito D, et al.: Evaluation of 18F-2-deoxy-2-fluoro- glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. Br J Cancer 2007;97:1493-1498.
21. Stahl A, Ott K, Weber WA, et al.: FDG PET imaging of locally advanced gastric carcinomas: Correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003;30:288-295.
22. Yamada A, Oguchi K, Fukushima M, et al.: Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: Relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression. Ann Nucl Med 2006;20:597-604.
23. Mukai K, Ishida Y, Okajima K, et al.: Usefulness of preoperative FDG-PET for detection of gastric cancer. Gastric Cancer 2006;9:192-196.
24. De Potter T, Flamen P, Van Cutsem E, et al.: Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med Mol Imaging 2002;29:525-529.
25. Jones DB: Role of endoscopic ultrasound in staging upper gastrointestinal cancers. ANZ J Surg 2007;77:166-172.
26. Ganpathi IS, So JB, Ho KY: Endoscopic ultrasonography for gastric cancer: Does it influence treatment? Surg Endosc 2006;20:559-562.
27. Habermann CR, Weiss F, Riecken R, et al.: Preoperative staging of gastric adenocarcinoma: Comparison of helical CT and endoscopic US. Radiology 2004;230:465-471.
28. Davies AR, Deans DA, Penman I, et al.: The multidisciplinary team meeting improves staging accuracy and treatment selection for gastro-esophageal cancer. Dis Esophagus 2006;19:496-503.
29. Di Raimondo F, Caruso L, Bonanno G, et al.: Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma? Ann Oncol 2007;18:351-356.
30. Rosai J, Ackerman L: Surgical pathology, 9th edition. Edinburgh: Mosby 2004.
31. Hayashi N, Ito I, Yanagisawa A, et al.: Genetic diagnosis of lymph-node metastasis in colorectal cancer. Lancet 1995;345:1257-1259.
32. Wu ZY, Li JH, Zhan WH, et al.: Effect of lymph node micrometastases on prognosis of gastric carcinoma. World J Gastroenterol 2007;13:4122-4125.
33. Maehara Y, Oshiro T, Endo K, et al.: Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of recurrence. Surgery 1996;119:397-402.
34. Herrera L, Villarreal JR: Incidence of metastases from rectal adenocarcinoma in small lymph nodes detected by a clearing technique. Dis Colon Rectum 1992;35:783-788.
35. Kooby DA, Suriawinata A, Klimstra DS, et al.: Biologic predictors of survival in node-negative gastric cancer. Ann Surg 2003;237:828-835.
36. Beahrs OH, Henson DE, Hutter RVP, et al.: Manual for staging of cancer, 4th edition. Philadelphia: Lippincott 1992.
37. Fleming ID, Cooper JS, Henderson DE: AJCC cancer staging manual, 5th edition. New York: Springer 1997.
38. Roder JD, Bottcher K, Busch R, et al.: Classification of regional lymph node metastasis from gastric carcinoma. German gastric cancer study group. Cancer 1998;82:621-631.
39. Ichikura T, Tomimatsu S, Uefuji K, et al.: Evaluation of the new American Joint Committee on Cancer/International Union Against Cancer classification of lymph node metastasis from gastric carcinoma in comparison with the Japanese classification. Cancer 1999;86:553-558.
40. Karpeh MS, Leon L, Klimstra D, et al.: Lymph node staging in gastric cancer: Is location more important than number? An analysis of 1,038 patients. Ann Surg 2000;232:362-371.
41. Greene FL, Page DL, Fleming ID, et al.: AJCC cancer staging manual, 6th edition. New York: Springer 2002.
42. Kajitani T: The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg 1981;11:127-139.
43. Smith DD, Schwarz RR, Schwarz RE: Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: Data from a large US-population database. J Clin Oncol 2005;23:7114-7124.
44. Coburn NG, Swallow CJ, Kiss A, et al.: Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer 2006;107:2143-2151.
45. Schwarz RE, Smith DD: Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol 2007;14:317-328.
46. Bouvier AM, Haas O, Piard F, et al.: How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer 2002;94:2862-2866.
47. Estes NC, MacDonald JS, Touijer K, et al.: Inadequate documentation and resection for gastric cancer in the United States: A preliminary report. Am Surg 1998;64:680-685.
48. Hundahl SA, Phillips JL, Menck HR: The national cancer data base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis. Cancer 2000;88:921-932.
49. Lee HK, Yang HK, Kim WH, et al.: Influence of the number of lymph nodes examined on staging of gastric cancer. Br J Surg 2001;88:1408-1412.
50. Elias D: Reflections and proposals for the standardization of lymphadenectomy for gastric carcinoma. Eur J Surg Oncol 2000;26:6-10.
51. Berger AC, Sigurdson ER, LeVoyer T, et al.: Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005;23:8706-8712.
52. Marchet A, Mocellin S, Ambrosi A, et al.: The ratio between metastatic and examined lymph nodes (N ratio) is an independent prognostic factor in gastric cancer regardless of the type of lymphadenectomy: Results from an italian multicentric study in 1853 patients. Ann Surg 2007;245:543-552.
53. Kattan MW, Karpeh MS, Mazumdar M, et al.: Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 2003;21:3647-3650.
54. Novotny AR, Schuhmacher C, Busch R, et al.: Predicting individual survival after gastric cancer resection: Validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann Surg 2006;243:74-81.
55. Bonenkamp JJ, Songun I, Hermans J, et al.: Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995;345:745-748.
56. Hartgrink HH, van de Velde CJ, Putter H, et al.: Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004;22:2069-2077.
57. Khatri VP, Douglass HO, Jr.: D2.5 dissection for gastric carcinoma. Arch Surg 2004;139:662-669, discussion 669.
58. Yonemura Y, Wu CC, Fukushima N, et al.: Metastasis in paraaortic lymph nodes in patients with advanced gastric cancer, treated with extended lymphadenectomy. Hepatogastroenterology 2007;54:634-638.
59. Wagner PK, Ramaswamy A, Ruschoff J, et al.: Lymph node counts in the upper abdomen: Anatomical basis for lymphadenectomy in gastric cancer. Br J Surg 1991;78:825-827.
60. Gervasoni JE, Jr., Taneja C, Chung MA, et al.: Biologic and clinical significance of lymphadenectomy. Surg Clin North Am 2000;80:1631-1673.
61. Siewert JR, Bottcher K, Roder JD, et al.: Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German gastric carcinoma study group. Br J Surg 1993;80:1015-1018.
62. Kim JP: Current status of surgical treatment of gastric cancer. J Surg Oncol 2002;79:79-80.
63. Cuschieri A, Fayers P, Fielding J, et al.: Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: Preliminary results of the MRC randomised controlled surgical trial. The surgical cooperative group. Lancet 1996;347:995-999.
64. Bonenkamp JJ, Hermans J, Sasako M, et al.: Extended lymphnode dissection for gastric cancer. N Engl J Med 1999;340:908-914.
65. Cuschieri A, Weeden S, Fielding J, et al.: Patient survival after D1 and D2 resections for gastric cancer: Long-term results of the MRC randomized surgical trial. Surgical co-operative group. Br J Cancer 1999;79:1522-1530.
66. Dent DM, Madden MV, Price SK: Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg 1988;75:110-112.
67. Robertson CS, Chung SC, Woods SD, et al.: A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 1994;220:176-182.
68. Wanebo HJ: Surgical quality control - A herculean task not easily achieved the Dutch gastric trial as a primer. Gastric Cancer 1998;1:93-94.
69. McCulloch P, Nita ME, Kazi H, et al.: Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2004;4: CD001964.
70. Parikh D, Johnson M, Chagla L, et al.: D2 gastrectomy: Lessons from a prospective audit of the learning curve. Br J Surg 1996;83:1595-1599.
71. Bonenkamp JJ, Hermans J, Sasako M, et al.: Quality control of lymph node dissection in the Dutch randomized trial of D1 and D2 lymph node dissection for gastric cancer. Gastric Cancer 1998;1:152-159.
72. Marubini E, Bozzetti F, Miceli R, et al.: Lymphadenectomy in gastric cancer: Prognostic role and therapeutic implications. Eur J Surg Oncol 2002;28:406-412.
73. Hazard L, O'Connor J, Scaife C: Role of radiation therapy in gastric adenocarcinoma. World J Gastroenterol 2006;12:1511-1520.
74. Nashimoto A, Nakajima T, Furukawa H, et al.: Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosanegative gastric cancer: Japan clinical oncology group 9206-1. J Clin Oncol 2003;21:2282-2287.
75. Wanebo HJ, Kennedy BJ, Chmiel J, et al.: Cancer of the stomach. A. Patient care study by the American College of Surgeons. Ann Surg 1993;218:583-592.
76. Degiuli M, Sasako M, Calgaro M, et al.: Morbidity and mortality after D1 and D2 gastrectomy for cancer: Interim analysis of the italian gastric cancer study group (IGCSG) randomised surgical trial. Eur J Surg Oncol 2004;30:303-308.
77. Sasako M, Sano T, Yamamoto S, et al.: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. 2008.
78. Fass J, Schumpelick V: Principles of radical surgery in gastric carcinoma. Hepatogastroenterology 1989;36:13-17.
79. Yu W, Choi GS, Chung HY: Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006;93:559-563.
80. Douglass HO, Jr., Hundahl SA, Macdonald JS, et al.: Gastric cancer: D2 dissection or low maruyama index-based surgery - A debate. Surg Oncol Clin N Am 2007;16:133-155.
81. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
82. Hundahl SA, Macdonald JS, Benedetti J, et al.: Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: The effect of undertreatment. Ann Surg Oncol 2002;9:278-286.
83. Peeters KC, Hundahl SA, Kranenbarg EK, et al.: Low maruyama index surgery for gastric cancer: Blinded reanalysis of the Dutch D1-D2 trial. World J Surg 2005;29:1576-1584.
84. Lee SI, Choi YS, Park DJ, et al.: Comparative study of laparoscopy-assisted distal gastrectomy and open distal gastrectomy. J Am Coll Surg 2006;202:874-880.
85. Pugliese R, Maggioni D, Sansonna F, et al.: Total and subtotal laparoscopic gastrectomy for adenocarcinoma. Surg Endosc 2007;21:21-27.
86. Kitagawa Y, Fujii H, Mukai M, et al.: The role of the sentinel lymph node in gastrointestinal cancer. Surg Clin North Am 2000;80:1799-1809.
87. Orsenigo E, Tomajer V, Di Palo S, et al.: Sentinel node mapping during laparoscopic distal gastrectomy for gastric cancer. Surg Endosc 2008;22:118-121.
88. Hundley JC, Shen P, Shiver SA, et al.: Lymphatic mapping for gastric adenocarcinoma. Am Surg 2002;68:931-935.
89. Ryu KW, Lee JH, Kim HS, et al.: Prediction of lymph nodes metastasis by sentinel node biopsy in gastric cancer. Eur J Surg Oncol 2003;29:895-899.
90. Kitagawa Y, Fujii H, Kumai K, et al.: Recent advances in sentinel node navigation for gastric cancer: A paradigm shift of surgical management. J Surg Oncol 2005;90:147-151, discussion 151-152.
91. Lim RB, Wong JH: Sentinel lymphadenectomy in gynecologic and solid malignancies other than melanoma and breast cancer. Surg Clin North Am 2000;80:1787-1798.
92. Lordick F, Siewert JR: Recent advances in multimodal treatment for gastric cancer: A review. Gastric Cancer 2005;8:78-85.
93. Kim S, Lim DH, Lee J, et al.: An observational study suggesting clinical benefit for adjuvant post-operative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 2005;63:1279-1285.
94. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
95. Sakuramoto S, Sasako M, Yamaguchi T, et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820.
96. Cho BC, Jeung HC, Choi HJ, et al.: Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single institute. J Surg Oncol 2007;95:461-468.
97. Kim SH, Karpeh MS, Klimstra DS, et al.: Effect of microscopic resection line disease on gastric cancer survival. J Gastrointest Surg 1999;3:24-33.
98. Martin RC II, Jaques DP, Brennan MF, et al.: Achieving RO resection for locally advanced gastric cancer: Is it worth the risk of multiorgan resection? J Am Coll Surg 2002;194:568-577.
99. Martin RC II, Jaques DP, Brennan MF, et al.: Extended local resection for advanced gastric cancer: Increased survival versus increased morbidity. Ann Surg 2002;236:159-165.